Clinical Report: Prescription Trends of Leucovorin for Pediatric Patients Diagnosed with Autism Spectrum Disorder

Overview

Revise to specify the timeline of the announcement and its correlation with prescription trends.

Background

Leucovorin, a form of folic acid, has been suggested as a potential treatment for speech-related deficits in children with ASD, although large-scale studies confirming its efficacy are lacking. The recent surge in interest and prescriptions following public endorsements raises concerns about the appropriateness of its use in this population. Understanding prescribing trends is crucial for ensuring safe and effective treatment practices.

Data Highlights

Key Findings

• Leucovorin prescription rates remained stable for two years before increasing sharply in early 2025.
• After the September 2025 announcement, prescriptions rose over 24-fold compared to the previous two years.
• Data included 838,801 patients with ASD contributing over 11 million outpatient encounters.
• Prescription rates plateaued but remained elevated in late 2025 and early 2026.
• Media coverage and public endorsements may have influenced prescribing behaviors significantly.

Clinical Implications

Highlight the importance of following clinical guidelines and the risks associated with off-label use.

Conclusion

Reinforce the need for further research and the impact of external factors on prescribing practices.

Related Resources & Content

1. Associated Press Health, AP News, 2025 -- Unexpected Reaction from Physician Following Trump's Announcement on Leucovorin for Autism Treatment
2. conexiant, 2025 -- FDA Approves Therapy for Cerebral Folate Deficiency
3. Drugs - Real World Outcomes, Springer, 2016 -- Medication Utilization and Polypharmacy in Adults with Autism Covered by Medicaid: A Retrospective Cross-Sectional Study
4. Interim Guidance from the American Academy of Pediatrics, AAP, 2025 -- Use of Leucovorin in Autistic Pediatric Patients
5. Federal Register, 2025 -- Approval of Previously Withdrawn New Drug Application for WELLCOVORIN (Leucovorin Calcium) Tablets
6. Child Neurology Society, 2026 -- Statement on Leucovorin Use in Autism Spectrum Disorders
7. Frye et al., Molecular Psychiatry, 2016 -- Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial
8. BMC Psychiatry (Springer) — Investigation of Plasma and Urinary Neurotransmitter Levels in Chinese Pediatric Patients with Autism Spectrum Disorder
9. FDA finds little evidence that the generic drug leucovorin can help people with autism
10. Interim Guidance from the American Academy of Pediatrics: Use of Leucovorin in Autistic Pediatric Patients
11. Federal Register :: Approval of Previously Withdrawn New Drug Application for WELLCOVORIN (Leucovorin Calcium) Tablets
12. Child Neurology Society Statement on Leucovorin Use in
13. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial | Molecular Psychiatry
14. Folinic acid improves the score of Autism in the EFFET placebo-controlled randomized trial - PubMed
15. Safety and Efficacy of High-Dose Folinic Acid in Children with Autism: The Impact of Folate Metabolism Gene Polymorphisms
16. Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis